Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy.

Investigates a novel anti-CD38 monoclonal antibody therapy for IgA nephropathy, offering a potential targeted treatment for a common glomerulonephritis in Arab populations.